This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
A supplement is a drug for interaction purposes, and the fact that it is sold without a prescription tells you nothing about whether it interacts. The paperwork is usually worse rather than better.
That is one dataset and I would not build a rule on it.
Post #60 put the caveat in the right place and I want to underline it.
Worth stating the null on Warfarin and altered intake before we explain it: the observation may be nothing. That possibility deserves a sentence and usually does not get one.
The arithmetic in post #62 is right; the assumption feeding it is the part to check.
Anticoagulants: no direct interaction with the compounds in this class. Weight loss and body composition changes might affect the clearance or effect of warfarin if you are on it; monitoring INR more frequently during weight loss is reasonable.
My position on Warfarin and altered intake is current rather than settled. I have revised it once already and I expect to again, so treat it accordingly.
Taking post #62 at face value and following it one step further.
Gastrointestinal symptoms from one compound can mask or mimic an interaction with another. Introducing two changes at once makes attribution impossible, which is an argument for spacing them.
Post #64 and I disagree about the size of the effect, not about the direction.
Reporting rather than recommending, on Warfarin and altered intake. What happened is above. Whether it should have is a different question and not one I am qualified to answer.
A pharmacist can answer most questions in this subcategory in a few minutes with access to a proper interaction database, and that access is the thing a forum does not have.
I would be glad to be shown a cleaner way of putting this.
This follows post #66 rather than contradicting it.
Offering a way to settle Warfarin and altered intake rather than another opinion about it. Two measurements, taken the same way, a fortnight apart. If the difference is within the noise, the question was not answerable at this precision.
Insulin interaction: semaglutide and tirzepatide are not contraindicated with insulin but the combination carries hypoglycemia risk if insulin doses are not adjusted. That is a reason for close monitoring, not for avoiding the combination.
Anyone who has looked at this more carefully, please correct the record.
Worth separating Warfarin and altered intake as a question about the compound from Warfarin and altered intake as a question about the documentation. They get answered by different people and only one of them is answerable here.
SGLT2 inhibitors: frequently co-administered and relevant to renal and cardiovascular discussion, not to interactions. There is no pharmacokinetic interaction of concern.
I would treat that as a working assumption and revisit it.
Adding the measurement that post #71 says would settle it.
Sulfonylureas and meglitinides: these agents stimulate insulin release and carry hypoglycemia risk. Combining them with semaglutide or tirzepatide requires dose adjustment of the secretagogue and close monitoring. The combination is not contraindicated but requires active management.
Before the thread moves on from Warfarin and altered intake — what is the sample size behind the claim? I am not being difficult; I have seen the same figure quoted from an n of four and from an n of four hundred.
Quietly grateful for the plain phrasing. Not every thread gets that.
Building on post #77 rather than restating it.
Insulin interaction: semaglutide and tirzepatide are not contraindicated with insulin but the combination carries hypoglycemia risk if insulin doses are not adjusted. That is a reason for close monitoring, not for avoiding the combination.
This follows post #80 rather than contradicting it.
I would put moderate confidence on the mainstream reading of Warfarin and altered intake and no more. That is not scepticism for its own sake; it is where the sourcing actually stops.
The question underneath Warfarin and altered intake is usually "how would I tell?" rather than "what is true?", and that one has a method attached to it.
Write down what you would expect to see under each hypothesis before you collect anything. If they predict the same observation, collecting it will not help.
Anticoagulant questions come up regularly and are the clearest case for professional advice rather than discussion, because the consequence of being wrong is not gradual.
If this contradicts something upthread, the upthread version may well be the better one.
Anticoagulants: no direct interaction with the compounds in this class. Weight loss and body composition changes might affect the clearance or effect of warfarin if you are on it; monitoring INR more frequently during weight loss is reasonable.
I am confident about the direction and much less about the magnitude.
On post #83 — agreed on the reasoning, with one qualification.
On Warfarin and altered intake: the maintained page in the documentation commons covers the general case with citations and a review date, which is more reliable than any reply here including this one.
The confident answers on Warfarin and altered intake and the well-sourced answers are not the same answers, which is the most useful thing I have learned reading this category.
The most defensible general position in this subcategory: identify the plausible mechanism, check whether it has been studied, and where it has not, say that rather than filling the gap.
The number is defensible. The precision I gave it is not.
The reason Warfarin and altered intake keeps being re-asked is that the answer is conditional and people quote it without the condition. It is not that the answer is unknown.